NXTCL.ST
NextCell Pharma AB [NXTCL.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NXTCL.ST Stock Summary
Top 10 Correlated ETFs
NXTCL.ST
Top 10 Correlated Stocks
NXTCL.ST
In the News
NXTCL.ST Financial details
Company Rating
-
Market Cap
97.98M
Income
-40.41M
Revenue
12.22M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
17
Optionable
No
Shortable
Yes
Earnings
28 Jan 2022
P/E
-2.24
Forward P/E
-
PEG
-1.23
P/S
8.7
P/B
1.16
P/C
-
P/FCF
-1.84
Quick Ratio
6.6
Current Ratio
6.67
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.17
EPS next Y
-
EPS next Q
-
EPS this Y
17.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-3.27%
Revenue last 5Y
41.04%
Revenue Q/Q
50.05%
EPS Q/Q
12%
-
-
-
-
SMA20
-64.38%
SMA50
-68.77%
SMA100
-40.23%
Inst Own
-
Inst Trans
-
ROA
-44%
ROE
-44%
ROC
-0.52%
Gross Margin
-9%
Oper. Margin
-405%
Profit Margin
-389%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.19-6.54
52W High
-82.33%
52W Low
-47%
RSI
30.54
Rel Volume
6.93
Avg Volume
38.21K
Volume
264.67K
Perf Week
9.96%
Perf Month
-67.28%
Perf Quarter
-39.43%
Perf Half Y
-39.43%
-
-
-
-
Beta
0.71
-
-
Volatility
0.07%, 0.95%
Prev Close
-7.02%
Price
1.06
Change
-8.62%
Company Profile
- Volume Average 38.21K
- Market Capitalization 97.98M
- Employee 17
- CEO Dr. Mathias Svahn Ph.D.
- Headquarters Huddinge,SE
- IPO Date 2017-07-13
-
Website
https://www.nextcellpharma.com 
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
